Cover Image

Morroniside ameliorates glucocorticoid-induced osteoporosis and promotes osteoblastogenesis by interacting with sodium-glucose cotransporter 2

AbstractContext Morroniside (MOR) possesses antiosteoporosis (OP) effects, but its molecular target and relevant mechanisms remain unknown.Objective We investigated the effects of MOR on glucocorticoid-induced OP and osteoblastogenesis and its underlying mechanisms.Materials and methods The effects...

Full description

Saved in:

Bibliographic Details
Main Authors:	Hou-Zhi Yang (Author), Runbei Dong (Author), Yutao Jia (Author), Yuqiao Li (Author), Gan Luo (Author), Tianhao Li (Author), Yao Long (Author), Shuang Liang (Author), Shanshan Li (Author), Xin Jin (Author), Tianwei Sun (Author)
Format:	Book
Published:	Taylor & Francis Group, 2023-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
by: Jun Tang, et al.
Published: (2022)

Inhibitors of sodium-glucose cotransporter 2: risk of ketoacidosis
by: T. M. Bukatina, et al.
Published: (2018)

Bibliometric and visualized analysis of sodium-Glucose cotransporter 2 inhibitors
by: He Sun, et al.
Published: (2023)

Bibliometric Study of Sodium Glucose Cotransporter 2 Inhibitors in Cardiovascular Research
by: Lu Chen, et al.
Published: (2020)

Sodium-glucose cotransporter 2 inhibitors and neurological disorders: a scoping review
by: Thahesh Tharmaraja, et al.
Published: (2022)

Promising role of sodium-glucose cotransporter-2 inhibitors in IgA nephropathy
by: Samaneh Zandifar, et al.
Published: (2023)

Sodium-glucose cotransporter 2 inhibitors: mechanisms of cardiorenal protection: A review
by: Marina V. Leonova
Published: (2024)

Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Heart Failure: An Update
by: Nicia I. Profili, et al.
Published: (2024)

Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy
by: Sanaa Bardaweel, et al.
Published: (2022)

A Potential Mechanism of Cardio-Renal Protection with Sodium-Glucose Cotransporter 2 Inhibitors: Amelioration of Renal Congestion
by: Satoru Kuriyama
Published: (2019)

A Role for Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Chronic Kidney Disease: A Mini Review
by: Jinfang Song, et al.
Published: (2023)

Induction of CYP3A by morroniside in rats
by: Shan Xiong, et al.
Published: (2015)

Influence of sodium/glucose cotransporter-2 inhibitors on the incidence of acute kidney injury: a meta-analysis
by: Qian Wang, et al.
Published: (2024)

Sodium/glucose cotransporter 2 and renoprotection: From the perspective of energy regulation and water conservation
by: Kento Kitada, et al.
Published: (2021)

Sodium-glucose cotransporter-2 inhibitors: A potential novel treatment for Lafora disease?
by: Paola Imbrici, et al.
Published: (2024)

Characterization and comparison of sodium-glucose cotransporter 2 inhibitors in pharmacokinetics, pharmacodynamics, and pharmacologic effects
by: Atsuo Tahara, et al.
Published: (2016)

Differential cardiovascular profiles of sodium-glucose cotransporter 2 inhibitors: critical evaluation of empagliflozin
by: Sanon VP, et al.
Published: (2017)

The Role of Sodium-Glucose Cotransporter-2 Inhibition in Heart Failure with Preserved Ejection Fraction
by: Lindsay Brust-Sisti, et al.
Published: (2022)

An Overview of the Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Hematological Parameters in Diabetic Patients
by: Ghada Ahmed, et al.
Published: (2023)

Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin
by: Daniel A. Kelmenson MD, et al.
Published: (2017)

The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic review and meta-analysis of randomized controlled trials
by: Dongmei Wang, et al.
Published: (2022)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
by: Moritz Mahling, et al.
Published: (2019)

Inhibition of Sodium-GlucoseCotransporter 2 with Dapagliflozin in Han: SPRD Rats with Polycystic Kidney Disease
by: Daniel Rodriguez, et al.
Published: (2015)

Polypharmacy influences the renal composite outcome in patients treated with sodium‐glucose cotransporter 2 inhibitors
by: Kazuo Kobayashi, et al.
Published: (2022)

Sodium-Glucose Cotransporter 2 Inhibitors Work as a "Regulator" of Autophagic Activity in Overnutrition Diseases
by: Kazuhiko Fukushima, et al.
Published: (2021)

Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report
by: Miho Nakamura, et al.
Published: (2020)

Sodium Glucose Cotransporter-2 Inhibitors in Non-Diabetic Kidney Disease: Evidence in Experimental Models
by: Giovanna Castoldi, et al.
Published: (2024)

Sodium-glucose cotransporter-2 inhibitors and risk for genitourinary infections in older adults with type 2 diabetes
by: Navya Varshney, et al.
Published: (2021)

Sodium-glucose cotransporter-2 (SGLT2) inhibitors and the reporting of falls and fractures: an european pharmacovigilance analysis
by: Annamaria Mascolo, et al.
Published: (2023)

Quality of methodological reporting of randomized clinical trials of sodium-glucose cotransporter-2 (sglt2) inhibitors
by: Hadeel Alfahmi, et al.
Published: (2017)

Cementocyte-derived extracellular vesicles regulate osteoclastogenesis and osteoblastogenesis
by: Jiajun Li, et al.
Published: (2024)

A review of the sources and pharmacological research of morroniside
by: Pengliang Shi, et al.
Published: (2024)

Amelioration of pancreatic fat accumulation in Japanese type 2 diabetes patients treated with sodium‐glucose cotransporter 2 inhibitors: a retrospective study
by: Tomomi Horii, et al.
Published: (2021)

The effects of sodium-glucose cotransporter 2 inhibitors on hepatocellular carcinoma: From molecular mechanisms to potential clinical implications
by: Konstantinos Arvanitakis, et al.
Published: (2022)

Highly selective sodium glucose cotransporter type 2 inhibitor empagliflozin neuroprotective potential in chronic brain dyscirculation
by: Оksana S. Fuks, et al.
Published: (2023)

Quantitative effects of sodium-glucose cotransporter-2 inhibitors dapagliflozin and empagliflozin on quality of life in heart failure patients
by: Dong-Dong Wang, et al.
Published: (2022)

Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes
by: Derosa G, et al.
Published: (2018)

Comparative Pharmacokinetics and Pharmacodynamics of a Novel Sodium-Glucose Cotransporter 2 Inhibitor, DWP16001, with Dapagliflozin and Ipragliflozin
by: Min-Koo Choi, et al.
Published: (2020)

In Vitro Metabolism of DWP16001, a Novel Sodium-Glucose Cotransporter 2 Inhibitor, in Human and Animal Hepatocytes
by: Ju-Hyun Kim, et al.
Published: (2020)

Sodium-glucose cotransporter-2 inhibitors and incidence of atrial fibrillation in older adults with type 2 diabetes: a retrospective cohort analysis
by: Yujia Li, et al.
Published: (2024)